Our beneficial results in terms of rehospitalizations and NT-ProBNP reduction and the lack of serious adverse events are in line with previous research, and suggest that hospitalization for heart failure should be considered as an opportunity for the clinician to initiate canagliflozin treatment in the T2D patient hospitalized for HF at the moment of discharge. The gene discussed is NPPB; the disease is hydrops fetalis.